Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 286.52K | Year: 2015
DESCRIPTION provided by applicant Proliferative vitreoretinopathy PVR is characterized by membranes that develop on the surface of the retina after rhegmatogenous retinal detachments RRDs Because PVR membranes exert tractional forces on the retina they are the leading cause of failure after RRD surgery Despite additional surgical interventions the visual outcome still remains poor Prevention of PVR during the initial RRD surgery is preferable and will avoid such recurrent retinal detachment or even blindness Unfortunately all previous attempts to prevent PVR formation using different pharmacologic agents have been unsuccessful The two main pathological hallmarks of PVR membranes are proliferation and epithelial mesenchymal transition EMT of retinal pigment epithelium RPE cells RPE cells play a pivotal role in maintaining photoreceptor function and are normally differentiated and mitotically quiescent due to contact inhibition RRDs allow RPE cells to be dispersed in the vitreous cavity and become exposed to growth factors e g EGF FGF TGF VEGF and TNF and inflammatory cytokines e g IFN which result in proliferation and EMT into fibroblasts or myofibroblasts Our recent discovery provides insight into the mystery of how growth factors control the proliferation and EMT of RPE cells Using post confluent ARPE cells in an in vitro model we demonstrated that proliferation is coupled with EMT when contact inhibition is perturbed by EGTA followed by exposure to EGF and or FGF which activate canonical Wnt signaling In contrast proliferation ceases with full blown EMT followed by exposure to TGF which activates Smad ZEB signaling This baseline characterization establishes a framework for discovering new drugs which can prevent PVR by targeting both proliferation and EMT Transplantation of cryopreserved amniotic membrane AM has become a standard surgical procedure for ocular surface reconstruction to deliver anti inflammatory anti scarring and anti angiogenic actions to promote wound healing Recently we have purified and characterized an active AM matrix component termed heavy chain hyaluronic acid pentraxin HC HA PTX complex which retains AMandapos s aforementioned therapeutic actions In this SBIR Phase I application we propose to prove the concept that HC HA PTX can inhibit both canonical Wnt signaling and TGF induced Smad ZEB signaling in RPE cells to inhibit proliferation and EMT respectively Successful completion of these aims will allow us to move to Phase II in order to gather critical pre clinical safety and efficacy data for the IND submission to the FDA so that we may examine its therapeutic potential as a new class of biologics to prevent PVR in human patients PUBLIC HEALTH RELEVANCE Our published and preliminary studies support the hypothesis that the HC HA PTX complex purified from human amniotic membrane can suppress both proliferation and EMT of human RPE cells In this Phase I application we propose to prove the concept so that we may proceed with pre clinical safety and efficacy studies in Phase II to gather critical data for the IND application to the FDA Our ultimate goal is to develop HC HA PTX as a new class of biologics to prevent PVR in human patients Furthermore the success of achieving this product development program will pave the way to deploy HC HA PTX as a new class of biologics to treat inflammatory scarring diseases in the eye and other parts of the body
Tissuetech | Date: 2013-03-13
Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.
Tissuetech | Date: 2014-12-22
Provided herein are methods of isolating and expanding a plurality of multipotent stem cells. Also described are methods of expanding stem cells on a substrate comprising an HC-HA complex. Also described are isolated and expanded stem cells produced by the methods and uses thereof, including stem cell therapy, as niche cells for supporting other types of stem cells, or as bioreactors for the production of HC-HA complexes. Also described are uses of HC-HA complexes as a carrier for stem cells.
Tissuetech | Date: 2015-09-29
Disclosed herein, in certain embodiments, is an HCHA complex comprising hyaluronan and a heavy chain of II, wherein the transfer of the heavy chain of II is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HCHA complex comprising hyaluronan and a heavy chain of II, wherein the transfer of the heavy chain of II is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof.
Tissuetech | Date: 2013-04-08
Compositions containing about 0.6% to about 20% of tea tree oil are described. Some compositions are in the form of solutions, suspensions, spray, lotions, gels, pastes, medicated sticks, balms, cleansers (including shampoos and soaps), creams, or ointments. Also described are compositions and methods for use in treating ocular